Research

Mixed

Tirzepatide significantly reduces the apnea-hypopnea index (AHI) and body weight in patients with moderate to severe obstructive sleep apnea (OSA) and obesity, regardless of whether they are using positive airway pressure (PAP) therapy.

If you have moderate to severe sleep apnea and obesity, Tirzepatide is a newly FDA-approved treatment that significantly reduces breathing interruptions during sleep and leads to substantial weight loss (18-20%). It works not just by shrinking fat around the airway, but also by reducing inflammation and affecting brain signals related to sleep. You can use it alone or alongside your CPAP machine. Because rapid weight loss can affect muscle, you should combine this medication with strength training and nutritional counseling.

GoodSupportsHIGH confidence
Tirzepatide led to a clinically and statistically significant improvement in the AHI as compared to placebo... Tirzepatide was superior to placebo for OSA treatment in patients with or without concomitant PAP therapy.
Danielle A. D’Annibale et al. · Current Opinion in Pulmonary Medicine · 2025

Why this rating

Based on recent high-impact randomized controlled trials (SURMOUNT-OSA) and meta-analyses, though long-term data is still emerging.

Source

Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea

Danielle A. D’Annibale et al. · Current Opinion in Pulmonary Medicine · 2025

DOI 10.1097/mcp.0000000000001208

narrative_reviewCited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →